UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 27-4842691 (State or other jurisdiction of incorporation or organization) (I.R.S. E ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2023 Earnings Conference Call February 15, 2024 4:30 PM ET Company Participants Anne Crotteau - Investor Relations Eric Dube - Chief Executive Officer Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer Bill Rote - Senior Vice President of Research & Development Conference Call Participants Joseph Schwartz - Leerink Partners Greg Harrison - Bank of America Anupam Rama - JP Morgan Tyler Van Buren - TD Cow ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Naomi Eichenbaum - Vice President-Investor Relations Dr. Eric Dube - Chief Executive Officer Dr. Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer Dr. Bill Rote - Senior Vice President of Research & Development Conference Call Participants Anupam Rama - JP Morgan Maury Raycroft - Jefferies Greg Harrison - Bank of America Vami ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the transition period from ___________ to ___________ Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) _________________________________ FORM 10-Q _________________________________ ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Naomi Eichenbaum - Vice President-Investor Relations Eric Dube - Chief Executive Officer Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer Bill Rote - Senior Vice President of Research & Development Conference Call Participants Malcolm Kuno - JPMorgan Tyler Van Buren - TD Cowen Greg Harrison - Bank of America Joseph Schwartz - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________ FORM 10-Q _________________________________ ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact name of ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Naomi Eichenbaum - VP, IR Eric Dube - President, CEO and Director Jula Inrig - Chief Medical Officer Christopher Cline - CFO Peter Heerma - Chief Commercial Officer William Rote - SVP, Research and Development Conference Call Participants Maury Raycroft - Jefferies Greg Harrison - Bank of America Joseph Schwartz - SVB Securities Leon Wang - Barclays Liisa Bayko - Evercore ISI Laura Chico - W ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________ FORM 10-Q _________________________________ ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact name o ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Naomi Eichenbaum - VP, IR Eric Dube - President, CEO & Director Jula Inrig - Chief Medical Officer Christopher Cline - CFO Peter Heerma - Chief Commercial Officer William Rote - SVP, Research & Development Conference Call Participants Gregory Harrison - Bank of America Merrill Lynch Maurice Raycroft - Jefferies Joseph Schwartz - SVB Securities Lachlan Hanbury-Brown - William Blair & Co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 27-4842691 (State or other jurisdiction of incorporation or organization) (I.R.S. E ...